Alzheimer’s gold rush inspires $565M deal between Chinese pharma powerhouse and little German biotech

The ballooning controversy around Biogen and its Alzheimer’s drug isn’t deterring others from the gold rush — and the search is global.

China’s Simcere is licensing regional rights to a Phase IIb anti-amyloid drug from German biotech Vivoryon Therapeutics and taking the lead on clinical development...

Click to view original post